Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | PTGES | O14684 | 1/20 | 0.48 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.48 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.48 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | EPOR | P19235 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31062607 | 0.89 | LDHA (0.58) | ACHETDP1MAPK1LDHAPPARG | |
| SCHEMBL842374 | 0.88 | LMNA (0.49) | MEN1KMT2A | |
| SCHEMBL841079 | 0.88 | LMNA (0.49) | MEN1KMT2A | |
| SCHEMBL11834013 | 0.82 | ACHE (0.53) | ACHETDP1MAPK1LDHAPPARG | |
| SCHEMBL28162835 | 0.82 | LMNA (0.50) | MAPK1TSHRMEN1KMT2A | |
| SCHEMBL5434326 | 0.80 | PGR (0.51) | ACHEMAPK1PPARGPPARATSHR | |
| SCHEMBL27843715 | 0.79 | ALOX5 (0.52) | ACHETDP1MAPK1PPARGPPARA | |
| SCHEMBL27843714 | 0.79 | ALOX5 (0.52) | ACHETDP1MAPK1PPARGPPARA | |
| SCHEMBL5428157 | 0.79 | LPAR1 (0.59) | EPOR | |
| SCHEMBL3854880 | 0.79 | EPOR (0.54) | MEN1KMT2AEPOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020147334-A1 | Vitronectin Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147334-A1 | Vitronectin Receptor Antagonists | ADGRF1, FN1, CALCR | ACHE 3149/4885TDP1 4601/4885MAPK1 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.